糖代谢异常对缺血性脑卒中的影响及防治策略

摘要/Abstract

摘要： 糖代谢异常可通过多种途径导致不同程度的氧化反应、慢性炎症和内皮功能障碍等,进而损害血管重塑和生长,最终导致脑血管疾病及其诱因的发生。本文以国内外糖代谢异常与脑卒中的相关性研究为基础,探讨糖代谢异常对缺血性脑卒中的影响,以期指导因糖代谢异常所致缺血性脑卒中的预防及治疗。

关键词: 糖代谢异常, 缺血性脑卒中, 预防管理

Abstract: Abnormal glucose metabolism can lead to oxidative stress, chronic inflammation and endothelial dysfunction through multiple pathways, which may impair vascular remodeling and growth, and eventually lead to cerebrovascular disease and its triggers. Based on the study of the correlation between abnormal glucose metabolism and stroke, this paper discusses the influence of abnormal glucose metabolism on ischemic stroke, in order to guide the prevention and treatment of ischemic stroke caused by abnormal glucose metabolism.

Key words: Abnormal glucose metabolism, Ischemic stroke, Preventive management

中图分类号:

R743.3

刘志娟. 糖代谢异常对缺血性脑卒中的影响及防治策略[J]. 中华养生保健, 2024, 42(21): 169-172.

LIU Zhi-juan. The Impact of Abnormal Glucose Metabolism on Ischemic Stroke and Its Prevention and Treatment Strategies[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(21): 169-172.

参考文献

[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2022概要[J].中国循环杂志,2023,38(6):583-612.
[2] JOHNSTON S C, EASTON J D, FARRANT M, et al.Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA[J]. N Engl J Med,2018,379(3):215-225.
[3] 邵婉珍,张风娥,王森等.糖代谢异常对大骨节病软骨细胞功能的影响[J].四川大学学报(医版),2018,49(2):221-225,270.
[4] CAMPBELL B C V, KHATRI P. Stroke[J]. Lancet,2020,396(10244):129-142.
[5] HU C C, LOW A, O'CONNOR E, et al. Diabetes in ischaemic stroke in a regional Australian hospital: Uncharted territory[J]. Intern Med J,2022,52(4):574-580.
[6] 杨文新. 2型糖尿病患者TCD检测脑血管狭窄分析[J].中风与神经疾病杂志,2001,118(5):310.
[7] 高鹤,江思瑜,郭晓玲等.糖代谢紊乱与脑卒中的关系研究进展[J].承德医学院学报,2022,39(6):505-510.
[8] ZHU B, PAN Y, JING J, et al.Stress hyperglycemia and outcome of non-diabetic patients after acute ischemic stroke[J]. Front Neurol,2019,10:1003.
[9] PENG G, YAN J, CHEN L, et al.Glycometabolism reprogramming: Implications for cardiovascular diseases[J]. Prog Biophys Mol Biol,2023,179:26-37.
[10] FERRARI F, MORETTI A, VILLA R F.Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity[J]. Neural Regen Res,2022,17(2):292-299.
[11] BOSARGE P L, SHOULTZ T H, GRIFFIN R L, et al.Stress-induced hyperglycemia is associated with higher mortality in severe traumatic brain injury[J]. J. Trauma. Acute Care Surg,2015,79:289-294.
[12] JUSTER-SWITLYK K, SMITH A G.Updates in diabetic peripheral neuropathy[J]. F1000Res2016,5:F1000 Faculty Rev-738.
[13] TSIVGOULIS G, KATSANOS A H, MAVRIDIS D, et al.Association of baseline hyperglycemia with outcomes of patients with and without diabetes with acute ischemic stroke treated with intravenous thrombolysis: a propensity score-matched analysis from the SITS-ISTR registry[J]. Diabetes,2019,68:1861-1869.
[14] ZHANG H, YUE K, JIANG Z, et al.Incidence of stress-induced hyperglycemia in acute ischemic stroke: A systematic review and meta-analysis[J]. Brain Sci,2023,13(4):556.
[15] VISSEREN F L J, MACH F, SMULDERS Y M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J,2021,42:3227-3337.
[16] MAIDA C D, DAIDONE M, PACINELLA G, et al.Diabetes and ischemic stroke: An old and new relationship an overview of the Close Interaction between These Diseases[J]. Int J Mol Sci.2022,23(4):2397.
[17] TIGCHELAAR C, VAN ZUYLEN M L, HULST A H, et al. Elevated cerebrospinal fluid glucose levels and diabetes mellitus are associated with activation of the neurotoxic polyol pathway[J]. Diabetologia,2022,65:1098-1107.
[18] RAJCHGOT T, THOMAS S C, WANG J C, et al.Neurons and Microglia; A Sickly-Sweet Duo in Diabetic Pain Neuropathy[J]. Front. Neurosci,2019,13:25.
[19] HORTON W B, BARRETT E J.Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease[J]. Endocr Rev,2021,42(1):29-55.
[20] CONTRERAS C M, GUTIÉRREZ-GARCÍA A G. Cognitive impairment in diabetes and poor glucose utilization in the intracellular neural milieu[J]. Med. Hypotheses,2017,104:160-165.
[21] NORIEGA-CISNEROS R, CORTÉS-ROJO C, MANZO-AVALOS S, et al. Mitochondrial response to oxidative and nitrosative stress in early stages of diabetes[J]. Mitochondrion,2013,13:835-840.
[22] REHNI A K, NAUTIYAL N, PEREZ-PINZON M A, et al. Hyperglycemia/hypoglycemia-induced mitochondrial dysfunction and cerebral ischemic damage in diabetics[J]. Metab Brain Dis,2015,30:437-447.
[23] DIENEL G A.Brain glucose metabolism: Integration of energetics with function[J]. Physiol Rev,2018,99(1):949-1045.
[24] MAGISTRETTI P J, ALLAMAN I.Lactate in the brain: From metabolic end-product to signalling molecule[J]. Nat Rev Neurosci,2018,19(4):235-249.
[25] CUNNANE S C, TRUSHINA E, MORLAND C, et al.Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing[J]. Nat Rev Drug Discov,2020,19(9):609-633.
[26] MUNIYAPPA R, CHEN H, MONTAGNANI M, et al.Endothelial dysfunction due to selective insulin resistance in vascular endothelium: Insights from mechanistic modeling[J]. Am J Physiol Endocrinol Metab,2020,319(3):E629-E646.
[27] DI PINO A, DEFRONZO R A.Insulin resistance and atherosclerosis: Implications for insulin-sensitizing agents[J]. Endocrine Rev,2019,40(6):1447-1467.
[28] GARBER A J, CRYER P E, SANTIAGO J V, et al.The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man[J]. J Clin Invest,1976,58:7-15.
[29] SMITH L, CHAKRABORTY D, BHATTACHARYA P, et al.Exposure to hypoglycemia and risk of stroke[J]. Ann N Y Acad Sci,2018,1431(1):25-34.
[30] 刘黎敏,卢昌均,周哲屹,等.血清内皮素1与降钙素基因相关肽在脑卒中发病机制中的作用研究进展[J].广西医学,2022,44(18):2159-2162,2175.
[31] JIN C, LI G, REXRODE K M, et al.Prospective study of fasting blood glucose and intracerebral hemorrhagic risk[J]. Stroke,2018,49:27-33.
[32] LIU J, RUTTEN-JACOBS L, LIU M, et al.Causal impact of type 2 diabetes mellitus on cerebral small vessel disease: A Mendelian randomization analysis[J]. Stroke,2018,49:1325-1331.
[33] VAN SLOTEN T T, SEDAGHAT S, CARNETHON M R, et al. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression[J]. Lancet Diabetes Endocrinol,2020,8:325-336.
[34] SHI H, GE Y, WANG H, et al.Fasting blood glucose and risk of Stroke: A Dose-Response meta-analysis[J]. Clin Nutr,2021,40(5):3296-3304.
[35] 赵晓营,任小红.脑卒中后应激性高血糖患者的血糖控制目标[J].解放军护理杂志,2016,33(11):26-28,65.
[36] 中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2 型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识[J].中华糖尿病杂志,2020,12(1):1-12.
[37] 葛均波,翁建平,曾强.2型糖尿病患者泛血管疾病风险评估与管理中国专家共识(2022版)[J].中国循环杂志,2022,37(10):974-990.
[38] NAUCK M A, MEIER J J, CAVENDER M A, et al.Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J]. Circulation,2017,136(9):849-870.
[39] SATTAR N, LEE M M Y, KRISTENSEN S L, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol,2021,9:653-662.
[40] STRAIN W D, FRENKEL O, JAMES M A, et al.Effects of semaglutide on stroke subtypes in type 2 diabetes: Post hoc analysis of the Randomized SUSTAIN 6 and PIONEER 6[J]. Stroke,2022,53(9):2749-2757.
[41] MASKERY M P, HOLSCHER C, JONES S P, et al.Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review[J]. J Cereb Blood Flow Metab,2021,41:14-30.
[42] ANDERSEN E S, LUND A, BAGGER J I, et al.Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?[J]. Diabetes Obes Metab,2018,20:1937-1943.